A month after gutting its internal drug discovery group, 23andMe is trudging along with the experimental medicines it’s ...

Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get ...

A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...

Eli Lilly's drug lebrikizumab has been approved for the treatment of eczema, or atopic dermatitis, a win for the company ...

The European Medicines Agency has solidified its recommendations to drugmakers that want to use single-arm designs in a ...

The mRNA-based Covid vaccines used by hundreds of millions of people may provide an unexpected benefit to some cancer ...

Three clinical-stage biotechs, three upsized offerings and three first-day share spikes. Last Friday's biotech IPO ...

A new treatment option for a wide range of patients diagnosed with neuroendocrine tumors could be approved in April, as final ...

Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...

Incyte said it has positive late-stage results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, ...

Summit and Akeso set the industry abuzz after their bispecific antibody beat Merck’s Keytruda in a Phase 3 lung cancer trial. Now, BioNTech is touting mid-stage data for its own lung cancer asset with ...